Nyxoah (NYXH) Projected to Post Quarterly Earnings on Thursday

Nyxoah (NASDAQ:NYXH) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.3510) per share and revenue of $11.00 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Nyxoah (NASDAQ:NYXH) last posted its earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.20). The business had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $8.64 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. On average, analysts expect Nyxoah to post ($1.44) EPS for the current fiscal year and ($0.79) EPS for the next fiscal year.

Nyxoah Stock Performance

Shares of NYXH opened at $0.90 on Thursday. The company has a current ratio of 2.38, a quick ratio of 2.31 and a debt-to-equity ratio of 0.44. The stock has a market cap of $34.88 million, a P/E ratio of -0.36 and a beta of 1.65. The company has a 50-day moving average of $1.38 and a two-hundred day moving average of $2.56. Nyxoah has a 12-month low of $0.80 and a 12-month high of $5.92.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Raymond James Financial set a $3.00 target price on Nyxoah in a research note on Tuesday. Cantor Fitzgerald lowered their target price on shares of Nyxoah to $3.00 and set an “overweight” rating for the company in a research note on Tuesday. Oppenheimer set a $4.00 target price on shares of Nyxoah in a research note on Thursday, August 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nyxoah in a report on Wednesday, August 19th. Finally, Robert W. Baird set a $2.31 price target on Nyxoah in a research note on Thursday, August 6th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Nyxoah has a consensus rating of “Hold” and a consensus target price of $3.55.

Nyxoah Company Profile

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.